A leaner version of the failed Icelandic genomics company, deCODE genetics, has emerged from the corporation's bankruptcy late last year. Dubbed the "New deCODE" in a company linkurl:statement;http://www.decode.com/news/news.php?story=112 released today (Jan 21), deCODE genetics ehf will focus less on in-house drug discovery, instead partnering with drug makers to translate its genetic discoveries into therapies. The new company will also continue to sell its diagnostics disease risk tests and its deCODEme personal genome scans, and will perform contract services, such as sequencing and genotyping. Much of deCODE's 10-year history has been plagued by linkurl:legal;http://www.the-scientist.com/news/display/25040/ and linkurl:financial;http://www.the-scientist.com/blog/display/55089/ woes. The resurrection of the company was made possible last week when a Delaware bankruptcy court OK'ed the sale deCODE Inc's subsidiary, linkurl:Islensk Erfdagreining,;http://www.decode.is/ to linkurl:Saga Investments,;http://www.corporationwiki.com/Florida/Boca-Raton/saga-investments-llc-4743111.aspx a heavy-hitter in the world of life science investment. Two men will lead deCODE genetics ehf -- Earl "Duke" Collier, past executive vice president at Genzyme and former...
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
